

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**Pembrolizumab for previously treated advanced or
metastatic urothelial cancer (CDF review TA519) [ID1536]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

None.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

Action Bladder Cancer UK: 'None known. Although women tend to be diagnosed at a later stage than men, meaning that their survival is lower.'

Would not need to be addressed by the committee (issues related to differences in prevalence or incidence of a disease cannot be addressed in a technology appraisal).

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

None.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Yes, in 'Other factors' section.

Approved by Associate Director (name): ...Linda Landells.....

Date: 1 November 2019

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

None were raised during consultation.

Potential equality issues were discussed during the appeal because older people and people with disabilities were disproportionately affected. However, the appeal panel could not identify any specific equality issues that arose during the appraisal and the patient group were not unusually defined by a protected characteristic other than the disability caused by the disease itself, which the committee took into account. Therefore, the committee concluded that no specific equality issues applied.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

The recommendations have not changed after consultation.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

The recommendations have not changed after consultation.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

The recommendations have not changed after consultation.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in section 3.34.

Approved by Associate Director (name): ...Linda Landells.....

Date: 02 March 2021